PT ENSEVAL PUTERA MEGATRADING TbkCOMPANY UPDATE

YTD 30 JUNE 2010 RESULTS

Table of Contents

• Enseval In BriefSection

I

• Business Overview Section

II

• Operational HighlightsSection

III

• Financial HighlightsSection

IV

I. Enseval In Brief

Milestones

Responding to the government regulation which require separation between role of distribution and role of marketing / manufacturing, PT Enseval was established in October 1973

In 1993, PT Enseval transferred all trading and distribution businesses to PT AryaGupta Cempaka, a wholly owned subsidiary, which later change its company name to PT Enseval Putera Megatrading

On 1 August 1994, the Company was listed on Indonesian Stock Exchange

Milestones

1994PT Enseval PuteraMegatrading Tbk conducted its Initial Public Offering

Incorporation of PT Renalmed Tiara Utama in July

PT Enseval Medika Prima, PT Global ChemindoMegatrading & PT Renalmed Tiara Utamastarted operations in October

20082007 Incorporation of Subsidiary : PT Enseval Medika Prima & PT Global ChemindoMegatrading

2003Incorporation of Subsidiary PT MileniaDharma Insani

Company Structures PT Enseval Putera Megatrading Tbk

PT Enseval PuteraMegatrading

Tbk

PT Tri Sapta Jaya

99.9%

PT Milenia Dharma Insani

100.0%

PT Enseval MedikaPrima

100.0%

PT Global ChemindoMegatrading

100.0%

PT Renalmed Tiara Utama

97.5%

II. Business Overview

Distribution & LogisticProduct Range : Ethical, OTC, Consumer Products, Medical Device &

Raw Material

Our service :

Warehousing

Inventory Management

Freight & Transportation

Sales & Support

Order-taking, Billing & Collection

Distribution & Logistic

Directly and Indirectly covers more than 1,000,000 outlets

Direct delivery to end customers

Cover most pharmacies & hospital

Cover 80% of consumer & health market

24 hour order fulfillment & 4-5 hour order fulfillment for prescription pharma

24 hour service for life saving drug

Offers value added services to customers :

- resource management, strategic sourcing & supply

- needs-basis marketing service

Medical DeviceProduct Range : Consumables, Instruments, Laboratories & Diagnostics, and

Products related to Laboratories Industry

The Company offers Marketing services for medical devices through its subsidiary, PT Enseval Medika Prima and Hemodialysis Treatment in collaboration with clinics and hospitals through PT Renalmed Tiara Utama.

The company has retained the trust & maintained good relationships with multi-national principals

Raw Material

Related to : Pharmaceutical Product, Food, Cosmetics & Veterinary

PT Global Chemindo Megatrading offers trading & marketing ofraw material and has extensive network and collaboration withMultinational Companies from different countries, such as : UnitedStates, Europe, China, Japan, Korea and other countries.

Healthcare Services Healthcare Services through Mitrasana Clinics ,with facilities such as:

Clinic, Pharmacy, Laboratory & Mini market, which now also offers Hemodialysis treatment.

Until 30 June 2010, The Company has 20 Clinics in Jakarta and its greater areas

Offered in 2 business models : direct investment & collaboration / joint operation models

III. Operational Highlights

Events Highlights

Infrastructures & Branches Development in branches, such as : Bekasi, Pematang Siantar.

The Company awarded as ‘Pharmaceutical distribution Company that has the most outlet’ from Rekor Bisnis Indonesia

The Company conducted its AGMS on May 18, 2010

New Principals In June 2010, PT Perkebunan Nusantara VIII joined as new

principal with its ready to drink tea product ‘ Walini Tea’

Branches The largest pharmaceutical distribution network throughout theIndonesian Archipelago with 42 Branches (EPM), 2 Regional DistributionCenter, Located in Jakarta & Surabaya & 23 Branches under subsidiarycompany (TSJ)

Human Resources Employs over 4,000 personnel with over 2,000 personnel are working in sales and

distribution

The Company continues to provide training for all employees to improved its human resources competencies

In year 2010, The Company continues to promote CONIM Program (ContinuosImprovement) to all staffs, both in Headquarters & in all Branches.

Principals Based on Categories

OTC Consumers Product Ethical

Major Principals

Principals Based on Categories

Medical Devices & Diagnostic Raw Material

Friesland Foods Domo

Major Principals

Infrastructures

Approximately 650 Transportation FleetApproximately 400 Motorcycles

More than 61.000 Pallets Size

The Usage of Oracle System as IT Platform

IV. Financial Highlights

Financial Highlights

Net Sales Operating Income

Until YTD 30 June 2010, The Company recorded Net Sales of IDR 4.4 trillion, with Operating Income amounting to IDR 99.1 billion

6.4

7.4

8.6

4.4

15.4% 16.1% 15.7%

10.6%

0.0%

2.0%

4.0%

6.0%

8.0%

10.0%

12.0%

14.0%

16.0%

18.0%

0.0

1.0

2.0

3.0

4.0

5.0

6.0

7.0

8.0

9.0

10.0

2007 2008 2009 H1 2010

NS ( IDR Trillion) Growth

307

363

484

143

4.8%4.9%

5.7%

3.2%

0.0%

1.0%

2.0%

3.0%

4.0%

5.0%

6.0%

0

100

200

300

400

500

600

2007 2008 2009 H1 2010

Operating Profit (IDR Billion) Operating Profit Margin

Financial Highlights

231

267

329

99

3.6%

3.6%3.9%

2.2%

0.0%

0.5%

1.0%

1.5%

2.0%

2.5%

3.0%

3.5%

4.0%

4.5%

0

50

100

150

200

250

300

350

2007 2008 2009 YTD 30 June 10

Net Income (IDR Million) Net Profit Margin

Net Income

102

117

144

63

0

20

40

60

80

100

120

140

160

2007 2008 2009 YTD 30 June 10

Net Income Per Share (IDR)

Net Income Per Share

Until YTD 30 June 2010, The Company Net Income was IDR 99.1 million , decline 32.9% YoY with Net Income Per Share of IDR 63

1,444

1,162

774

325 266

16

1,671

1,386

776

355

209

14

Consumer Products Ethical OTC Raw Material Medical Device Others

YTD 30 June 09 YTD 30 June 10 (IDR Billion)

9.2%

13.2%

0.3%

19.2%

15.7%

21.3%

Net Sales By Division

Sales Contribution

72%

28%

74%

26%

Kalbe Grup

3rd Party

YTD 30 June 2010 YTD 30 June 2009

Until YTD 30 June 10 Kalbe Group’s Sales contributes % of total sales, while the remaining % are from 3rd party Principals.

Consumer Products

37%

Ethical 31%

OTC 18%

Medical Device

5%

Raw Material 8%

Others0%

Sales Contribution

Consumer Products

36%

Ethical 29%

OTC20%

Medical Device

7%

Raw Material 8%

Others0%

YTD 30 June 2010

YTD 30 June 2009

2,518

378

2,896 3,045

429

3,474

Current Assets Non Current Assets

Total Assets

30 June 09 (IDR Billion)

30 June 10 (IDR Billion)

21.0%

13.6%

20.0%

Assets

1,438

35

1,473

1,752

82

1,833

Current Liablities Non Current Liabilities Total Liabilities

30 June09 (IDR Billion) 30 June 10(IDR Billion)

Liabilities & Equity

1,422

1,640

Equity

30 June 09 (IDR Billion) 30 June 10 (IDR Billion)

24.5%

15.3%

132.7%

21.8%

Thank You For further information, please contact :

PT Enseval Putera Megatrading Tbk.

Enseval Building, Kawasan Industri Pulogadung

Jalan Pulolentut No.10

Jakarta 13920 – Indonesia

Phone : 62-21-46822422 Fax : 62-21-4609039

Website : www.enseval.com

Email : investor.relations@enseval.com

IMPORTANT NOTICE

This presentation has been prepared for informational purposes only by PT Enseval Putera

Megatrading Tbk. (“Enseval” or the “Company”).

The information contained in this Presentation does not purport to be all-inclusive or to

contain all of the information that may be material to an investor’s decision. It should be

noted that the information contained in this Presentation is subjected to further review, and

that such information may be updated and/or amended from time to time as

circumstances change or more information becomes available. Some of those revisions or

changes may be material.

Each recipient of this Presentation should therefore perform their own independent

analysis of the business, operations, financial condition, creditworthiness, status and

affairs of Enseval. Each recipient should also conduct their own enquiries into the

adequacy, accuracy, and completeness of any information relating to Enseval, as the

information and data contained in this Presentation are not substitutes for the recipient’s

independent evaluation and analysis.

This presentation is not an offering document and will be updated regularly as necessary.